日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing

MK-8527 是一种新型的 HIV-1 逆转录酶易位抑制剂,具有延长给药时间的潜力。

Raheem, Izzat T; Girijavallabhan, Vinay; Fillgrove, Kerry L; Goh, Shih Lin; Bahnck-Teets, Carolyn; Huang, Qian; Li, Fangbiao; Wan, Bang-Lin; O'Donnell, Gregory T; Patteson, Jonathan B; Cilento, Maria E; Bennet, Amrith; Hayes, Robert P; Tummala, Srivanya; McHale, Carolyn; Wiltsie, Judyann; Ellis, Joan; Asante-Appiah, Ernest; Hazuda, Daria J; Hale, Jeffrey; Grobler, Jay A; Xu, Min; Diamond, Tracy L; Lai, Ming-Tain

Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy.

新型抗体药物偶联物 OBI-992 用于癌症治疗的临床前评价

Chang Ting-Yu, Lin Chun-Jung, Wen Shih-Ni, Wu Yi-Chen, Wei Cheng-Yen, Huang Jye-Yu, Tsao Yu-Hsuan, Chen Yu-Jung, Tang Wei-Chien, Wu Yuen-Chin, Lee Wei-Han, Huang Teng-Yi, Kuo Tzer-Min, Li Wan-Fen, Lai Ming-Tain

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system

使用基于 Quantum pBac 的 CAR-T 工程系统制造 CD20/CD19 靶向 iCasp9 可调节 CAR-TSCM 细胞

Peter S Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Po-Nan Wang, Yi-Fang Chang, Ming-Chih Chang, Yu-Cheng Chang, Shiou-Ling Jian, Jiann-Shiun Lai, Ming-Tain Lai, Wei-Cheng Yang, Chia-Ning Shen, Kuo-Lan Karen Wen, Sareina Chiung-Yuan Wu

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance

多拉韦林和伊斯拉曲韦具有互补的耐药谱,二者联合使用可形成高耐药屏障。

Lai, Ming-Tain; Feng, Meizhen; Xu, Min; Ngo, Winnie; Diamond, Tracy L; Hwang, Carey; Grobler, Jay A; Hazuda, Daria J; Asante-Appiah, Ernest

Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

伊斯拉曲韦具有较高的耐药屏障,并且与已批准的核苷类逆转录酶抑制剂(NRTIs)表现出不同的耐药性特征。

Diamond, Tracy L; Ngo, Winnie; Xu, Min; Goh, Shih Lin; Rodriguez, Silveria; Lai, Ming-Tain; Asante-Appiah, Ernest; Grobler, Jay A

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects

健康受试者从依非韦伦换用多拉韦林时多拉韦林药代动力学的评估

Yee, Ka Lai; Sanchez, Rosa I; Auger, Patrice; Liu, Rachael; Fan, Li; Triantafyllou, Ilias; Lai, Ming-Tain; Di Spirito, Mike; Iwamoto, Marian; Khalilieh, Sauzanne G

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

多拉韦林在临床相关浓度下可抑制常见非核苷类逆转录酶抑制剂相关突变体

Feng, Meizhen; Sachs, Nancy A; Xu, Min; Grobler, Jay; Blair, Wade; Hazuda, Daria J; Miller, Michael D; Lai, Ming-Tain

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways

利用多拉韦林(MK-1439)进行体外耐药性筛选,多拉韦林是一种新型非核苷类逆转录酶抑制剂,具有独特的突变发展途径。

Feng, Meizhen; Wang, Deping; Grobler, Jay A; Hazuda, Daria J; Miller, Michael D; Lai, Ming-Tain

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

体外表征新型 HIV-1 非核苷类逆转录酶抑制剂 MK-1439

Lai Ming-Tain, Feng Meizhen, Falgueyret Jean-Pierre, Tawa Paul, Witmer Marc, DiStefano Daniel, Li Yuan, Burch Jason, Sachs Nancy, Lu Meiqing, Cauchon Elizabeth, Campeau Louis-Charles, Grobler Jay, Yan Youwei, Ducharme Yves, Côté Bernard, Asante-Appiah Ernest, Hazuda Daria J, Miller Michael D